

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Nusse Roeland</u> (Last) (First) (Middle) <u>614 MCKINLEY PL NE</u> (Street) <u>MINNEAPOLIS MN 55413</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIO-TECHNE Corp [TECH]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ☒ Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/25/2025</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/25/2025		M		17,040	A	\$21.84	61,599	D	
Common Stock	08/25/2025		S		17,040	D	\$56.3608 ⁽¹⁾	44,559	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$21.84	08/25/2025		M			17,040	10/29/2016	10/28/2025	Common Stock	17,040	\$0	0	D	
Stock Options (Right to Buy)	\$25.3							10/26/2017	10/27/2026	Common Stock	15,940		15,940	D	
Stock Options (Right to Buy)	\$31.26							10/25/2018	10/26/2027	Common Stock	12,500		12,500	D	
Stock Options (Right to Buy)	\$44.96							10/24/2019	10/25/2028	Common Stock	7,592		7,592	D	
Stock Options (Right to Buy)	\$50.41							10/24/2020	10/24/2029	Common Stock	8,044		8,044	D	
Stock Options (Right to Buy)	\$63.92							10/28/2021	10/29/2030	Common Stock	6,028		6,028	D	
Stock Options (Right to Buy)	\$128.81							10/27/2022	10/28/2031	Common Stock	2,532		2,532	D	
Stock Options (Right to Buy)	\$73.94							10/26/2023	10/27/2032	Common Stock	3,460		3,460	D	
Stock Options (Right to Buy)	\$61.51							10/24/2024	10/26/2033	Common Stock	3,937		3,937	D	
Stock Options (Right to Buy)	\$68.37							(2)	10/24/2034	Common Stock	3,511		3,511	D	

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.21 to \$56.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.

Andrew Nick as Attorney-in-Fact
for Roeland Nusse pursuant to 08/27/2025
Power of Attorney previously filed

** Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.